Fulcrum Financial Statements From 2010 to 2025

FULC Stock  USD 3.02  0.10  3.21%   
Fulcrum Therapeutics financial statements provide useful quarterly and yearly information to potential Fulcrum Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Fulcrum Therapeutics financial statements helps investors assess Fulcrum Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Fulcrum Therapeutics' valuation are summarized below:
Gross Profit
16.6 M
Profit Margin
(0.12)
Market Capitalization
168.4 M
Enterprise Value Revenue
117.3999
Revenue
80 M
We have found one hundred twenty available fundamental signals for Fulcrum Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to verify all of Fulcrum Therapeutics' prevailing performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road.

Fulcrum Therapeutics Total Revenue

84 Million

Check Fulcrum Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fulcrum Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 1.8 M, Interest Income of 1.8 M or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 139, Dividend Yield of 0.0 or PTB Ratio of 1.92. Fulcrum financial statements analysis is a perfect complement when working with Fulcrum Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Fulcrum Therapeutics Correlation against competitors.
For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.

Fulcrum Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets180.2 M260.7 M95 M
Slightly volatile
Other Current Liabilities439.9 K463 K2.5 M
Slightly volatile
Total Current Liabilities14.6 M11 M8.8 M
Slightly volatile
Total Stockholder Equity157.9 M243 M82.2 M
Slightly volatile
Other Liabilities168.4 K177.3 KM
Pretty Stable
Property Plant And Equipment Net15.5 M9.6 M12 M
Pretty Stable
Accounts Payable1.1 M1.2 M2.1 M
Slightly volatile
Cash38.1 M58.2 M26.4 M
Slightly volatile
Non Current Assets Total13.2 M10.8 M8.1 M
Slightly volatile
Other Assets3.9 M3.7 M1.2 M
Slightly volatile
Cash And Short Term Investments147.7 M271.7 M85.1 M
Slightly volatile
Net Receivables1.7 M2.6 M959.6 K
Slightly volatile
Common Stock Total Equity62.8 K59.8 K21.4 K
Slightly volatile
Common Stock Shares Outstanding35.7 M53.9 M23.3 M
Slightly volatile
Liabilities And Stockholders Equity164.9 M296.3 M96.3 M
Slightly volatile
Non Current Liabilities Total7.6 M6.6 MM
Slightly volatile
Capital Surpluse739 M703.8 M234.9 M
Slightly volatile
Other Current Assets4.5 M4.3 M1.4 M
Slightly volatile
Other Stockholder Equity899.5 M856.7 M272.1 M
Slightly volatile
Total Liabilities22.3 M17.7 M12.8 M
Slightly volatile
Property Plant And Equipment Gross13 M23.8 MM
Slightly volatile
Total Current Assets166.9 M249.9 M86.9 M
Slightly volatile
Non Current Liabilities Other215.2 K226.6 K285 K
Pretty Stable
Common Stock74.9 K71.3 K23.5 K
Slightly volatile
Property Plant Equipment8.3 M7.9 M5.6 M
Slightly volatile
Short and Long Term Debt Total13.1 M12.4 M3.2 M
Slightly volatile
Current Deferred Revenue1.2 M1.3 M3.4 M
Very volatile
Capital Stock43.4 K54 K28 K
Slightly volatile

Fulcrum Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income1.8 M1.7 M727.7 K
Slightly volatile
Interest Income1.8 M1.7 M727.7 K
Slightly volatile
Depreciation And Amortization2.1 M2.5 M1.5 M
Slightly volatile
Selling General Administrative27.2 M36.4 M16 M
Slightly volatile
Other Operating Expenses86.9 M130.5 M58.2 M
Slightly volatile
Research Development62.6 M63.4 M40.5 M
Slightly volatile
Total Operating Expenses89.8 M99.8 M56.5 M
Slightly volatile
Reconciled Depreciation2.1 M1.6 M1.4 M
Slightly volatile
Total Other Income Expense Net10.6 M10.1 M2.5 M
Slightly volatile
Selling And Marketing Expenses1.7 MM2.1 M
Slightly volatile

Fulcrum Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation9.5 M14.6 M5.5 M
Slightly volatile
Begin Period Cash Flow46 M26.7 M25.8 M
Slightly volatile
Other Cashflows From Financing Activities1.3 M1.4 M20.5 M
Pretty Stable
Depreciation2.1 M1.6 M1.4 M
Slightly volatile
Capital Expenditures264.1 K278 K1.9 M
Pretty Stable
Total Cash From Financing Activities2.6 M2.7 M48.5 M
Slightly volatile
End Period Cash Flow38.9 M59.4 M26.9 M
Slightly volatile
Change To Netincome11.9 M15.4 M7.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio13913354.6361
Slightly volatile
PTB Ratio1.922.0257.0735
Slightly volatile
Days Sales Outstanding277263138
Slightly volatile
Book Value Per Share3.493.452.3923
Slightly volatile
Stock Based Compensation To Revenue4.994.751.679
Slightly volatile
Capex To Depreciation0.260.271.954
Slightly volatile
PB Ratio1.922.0257.0735
Slightly volatile
EV To Sales13412848.9286
Slightly volatile
Payables Turnover0.770.760.5868
Slightly volatile
Sales General And Administrative To Revenue14.0413.374.8189
Slightly volatile
Research And Ddevelopement To Revenue24.1923.0410.1364
Slightly volatile
Capex To Revenue0.140.160.1596
Pretty Stable
Cash Per Share3.663.472.4666
Slightly volatile
Days Payables Outstanding634633703
Slightly volatile
Income Quality0.640.840.8243
Pretty Stable
Current Ratio8.2715.946.2458
Slightly volatile
Tangible Book Value Per Share3.493.452.3923
Slightly volatile
Receivables Turnover1.361.433.1512
Pretty Stable
Shareholders Equity Per Share3.493.452.3923
Slightly volatile
Debt To Equity0.05030.052913.0992
Slightly volatile
Capex Per Share0.00910.00950.1358
Slightly volatile
Revenue Per Share0.050.05260.2912
Slightly volatile
Interest Debt Per Share0.190.21.6524
Slightly volatile
Debt To Assets0.04590.04834.0007
Slightly volatile
Price Book Value Ratio1.922.0257.0735
Slightly volatile
Days Of Payables Outstanding634633703
Slightly volatile
Ebt Per Ebit1.071.010.9917
Very volatile
Company Equity Multiplier1.631.262.266
Slightly volatile
Long Term Debt To Capitalization0.770.870.9453
Slightly volatile
Total Debt To Capitalization0.04810.05060.4985
Slightly volatile
Debt Equity Ratio0.05030.052913.0992
Slightly volatile
Quick Ratio8.2215.946.0986
Slightly volatile
Net Income Per E B T0.770.870.9417
Slightly volatile
Cash Ratio2.042.152.4054
Pretty Stable
Days Of Sales Outstanding277263138
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.191.161.1002
Very volatile
Price To Book Ratio1.922.0257.0735
Slightly volatile
Fixed Asset Turnover0.250.260.9558
Slightly volatile
Debt Ratio0.04590.04834.0007
Slightly volatile
Price Sales Ratio13913354.6361
Slightly volatile
Asset Turnover0.01190.01250.0559
Slightly volatile
Gross Profit Margin0.810.710.7288
Very volatile
Price Fair Value1.922.0257.0735
Slightly volatile

Fulcrum Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Fulcrum Therapeutics Financial Statements

Fulcrum Therapeutics stakeholders use historical fundamental indicators, such as Fulcrum Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Fulcrum Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Fulcrum Therapeutics' assets and liabilities are reflected in the revenues and expenses on Fulcrum Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Fulcrum Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.3 M1.2 M
Total Revenue80 M84 M
Cost Of Revenue82.6 M86.7 M
Stock Based Compensation To Revenue 4.75  4.99 
Sales General And Administrative To Revenue 13.37  14.04 
Research And Ddevelopement To Revenue 23.04  24.19 
Capex To Revenue 0.16  0.14 
Revenue Per Share 0.05  0.05 
Ebit Per Revenue(45.37)(43.10)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Fulcrum Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fulcrum Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fulcrum Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fulcrum Therapeutics Stock:
Check out the analysis of Fulcrum Therapeutics Correlation against competitors.
For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.16)
Revenue Per Share
1.291
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.05)
Return On Equity
(0.04)
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.